Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis

J Oncol Pract. 2019 Jun;15(6):343-345. doi: 10.1200/JOP.19.00012. Epub 2019 Apr 9.

Authors

Panagiotis J Vlachostergios¹, Julia T Geyer¹, John Miller², Rebecca Kosloff³, Himisha Beltran^{1

4}, Scott T Tagawa¹

Affiliations

¹ 1 Weill Cornell Medicine, New York, NY.
² 2 Riverside Medical Group, Peninsula Cancer Institute, Williamsburg, VA.
³ 3 Florida Cancer Specialists and Research Institute, Naples, FL.
⁴ 4 Dana-Farber Cancer Institute, Boston, MA.

PMID: 30964731
DOI: 10.1200/JOP.19.00012

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Anemia, Myelophthisic / physiopathology*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Bone Neoplasms / complications
Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary
Humans
Male
Pancytopenia / complications
Pancytopenia / drug therapy*
Pancytopenia / pathology
Prognosis
Prostatic Neoplasms, Castration-Resistant / complications
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab